Coated (e.g., Microcapsules) Patents (Class 424/490)
  • Patent number: 11813289
    Abstract: The invention provides compositions and methods that comprise encapsulated silver diamine fluoride or other antimicrobial materials for use in treatment of dental caries, for example.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: November 14, 2023
    Assignee: ADVANTAGE SILVER DENTAL ARREST, LLC
    Inventors: Peter M. Milgrom, Jong Seto
  • Patent number: 11807553
    Abstract: Decontamination of water using guar gum (GG) derivatives and applications thereof are provided herein. For water decontamination, guar gum cinnamate (GGCi) is fabricated into nanoparticles having a high surface area that facilitates the removal of water pollutants by adsorption. Owing to its high availability, low cost, slow biodegradability and high sustainability, GG is considered promising as a next generation cost effective green material for water decontamination.
    Type: Grant
    Filed: April 24, 2023
    Date of Patent: November 7, 2023
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Nagaraja Sreeharsha, Anroop B. Nair, Mahesh Attimarad, Katharigatta N. Venugopala, Bandar Aldhubiab, Sonia Kundu, Aalok Basu, Suvadra Das, Partha Roy, Teeka Sathiesh Roopashree
  • Patent number: 11806433
    Abstract: Described herein are alcohol-resistant oral pharmaceutical compositions and dosage forms that exhibit reduced drug release in the presence of alcohol. The compositions comprise a substrate comprising a controlled release formulation of lorazepam and an alcohol-resistant coating surrounding the substrate.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: November 7, 2023
    Assignee: EDGEMONT PHARMACEUTICALS, LLC TRUST
    Inventors: Douglas Saltel, Michael Vachon
  • Patent number: 11793758
    Abstract: The disclosure relates, among others, to methods for preparing pharmaceutical compositions that can be provided to the subject in oral form, comprising as an active ingredient: a protein with a mass of 10 kilodalton or more, a nucleic acid molecule of 15 nucleotides or more, or a combination thereof. The one or more active ingredients are distributed in particles in a way that facilitates the uptake of the particles by the intestine and the release of the active ingredient(s) into the blood stream.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: October 24, 2023
    Assignee: Bioralix B.V.
    Inventors: Bernardus Rademaker, Willem Adriaan Minnaard, Eduard Johannes Van Zwieten, Jacob Wieling
  • Patent number: 11793747
    Abstract: Self-regulating, osmotic, floating gastroretentive compositions that provide extended release, delayed release, and/or delayed extended release of active pharmaceutical agents, as well as, optionally, immediate release of the same or a different active pharmaceutical agent, are provided here. The gastroretentive compositions of the disclosure comprise a swellable, extended release, multilayer core comprising a push layer and a pull layer; a water-insoluble permeable elastic membrane surrounding the multilayer core; and an orifice (e.g., a laser-drilled orifice, a manually drilled orifice) on the pull-layer side of the dosage form. The gastric retention of the composition is controlled by rapid floating of the composition and expansion of the membrane.
    Type: Grant
    Filed: October 18, 2021
    Date of Patent: October 24, 2023
    Inventors: Navnit H. Shah, Dipen Desai, Wantanee Phuapradit, Jaydeep Vaghashiya, Kanji Meghpara
  • Patent number: 11763451
    Abstract: The disclosure describes imaging and therapy techniques comprising nanodroplets. More particularly, aspects of the disclosure relate to the use of nanodroplets to modify nanobubbles or microbubbles to provide improved imaging and/or therapeutic techniques and compositions.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: September 19, 2023
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Robert F. Mattrey, Caroline De Gracia Lux, Jacques Lux, Zhenghong Gao, Carlos J. Brambila
  • Patent number: 11759445
    Abstract: The present disclosure relates to use of Rivastigmine in the preparation of an anti-radiation medicament, and belongs to the field of medical technology. The present disclosure provides use of Rivastigmine in the preparation of an anti-radiation medicament. Researches show that Rivastigmine significantly promoted the proliferation of Lgr5+ stem cells receiving 10 Gy radiation (after being irradiated with 10 Gy radiation for 10 d, Lgr5+ stem cells cultured in a Rivastigmine-containing culture solution had an increment 14.2 times of that of the Lgr5+ stem cells cultured in a Rivastigmine-free culture solution). Rivastigmine also significantly reduced the mortality of mice after being irradiated with 10 Gy radiation (after receiving 10 Gy whole body irradiation, all the mice not intraperitoneally injected Rivastigmine died within 10 d; and for the mice intraperitoneally injected Rivastigmine, the survival rate of the mice was still greater than 40% 30 d later), and thus might have good radiation-proof effect.
    Type: Grant
    Filed: July 29, 2021
    Date of Patent: September 19, 2023
    Assignee: SOOCHOW UNIVERSITY
    Inventors: Qiu Chen, Fengmei Cui, Hongbin Yan
  • Patent number: 11752173
    Abstract: Provided are a modified mesenchymal stem cell and culture supernatant thereof, and a pharmaceutical composition comprising said cell or culture supernatant thereof. The mesenchymal stem cell is capable of expressing: (1) a first protein, which is selected from FGF21 or a variant thereof, or a first fusion protein comprising the FGF21 or the variant thereof and (2) a second protein, which is selected from GLP-1 or a variant thereof or a second fusion protein comprising the GLP-1 or the variant thereof. Also provided is the use of the modified mesenchymal stem cell and culture supernatant thereof, and the pharmaceutical composition comprising said cell or culture supernatant thereof in the treatment of metabolic diseases and in the preparation of a medicament for treating metabolic diseases.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: September 12, 2023
    Assignee: Beijing Jiyuan Biological Technology Co., Ltd.
    Inventors: Haifeng Duan, Binghua Xue, Jing Xie, Zhenli Zhang
  • Patent number: 11753485
    Abstract: The present application relates to polymer microparticle-metal nanoparticle composites, to methods of preparing polymer microparticle-metal nanoparticle composites and to uses of such composites. The methods comprise introducing into a microfluidic device, a composition comprising: a cationic metal nanoparticle precursor; a polymer microparticle precursor that comprises a plurality of photopolymerizable groups; and a photoreducer-photoinitiator; then irradiating the composition under conditions to simultaneously reduce the cationic metal and polymerize the photopolymerizable groups to obtain the composite.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: September 12, 2023
    Assignee: National Research Council of Canada
    Inventors: Lidija Malic, Xuefeng Zhang, Keith Morton, Teodor Veres
  • Patent number: 11753483
    Abstract: There is provided a method for producing hydroxypropyl methyl cellulose acetate succinate (HPMCAS), including an esterification step of reacting hydroxypropyl methyl cellulose with an acetylating agent and a succinoylating agent in the presence of an aliphatic carboxylic acid in a kneader reactor equipped with two or more stirring blades rotating around their own axes and orbitally revolving, to obtain a reaction product solution containing HPMCAS; a precipitation step of precipitating the HPMCAS by mixing the reaction product solution with water to obtain a suspension of the precipitated HPMCAS; and a washing and recovery step of washing the HPMCAS in the suspension and recovering the washed HPMCAS. Further, there is provided HPMCAS having yellowness at 20° C. of 15.0 or less, as determined in a 2% by mass solution of the HPMCAS in a mixed solvent of dichloromethane, methanol and water in a mass ratio of 44:44:10.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: September 12, 2023
    Assignee: Shin-Etsu Chemical Co., Ltd.
    Inventors: Taishi Kitaguchi, Junichi Matsubara, Mitsuhiro Yoshida
  • Patent number: 11730753
    Abstract: The present invention relates to pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride. More particularly, the present invention relates to a tablet composition comprising trifluridine, tipiracil hydrochloride and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
    Type: Grant
    Filed: March 2, 2019
    Date of Patent: August 22, 2023
    Assignee: Natco Pharma Limited
    Inventors: Tripuraneni Rama Swamy Chowdary, Bhavanasi Krishna Murthy, Yedluri Siddhartha, Bhat Pavan, Nannapaneni Venkaiah Chowdary
  • Patent number: 11723875
    Abstract: A water-soluble polyurethane derived from: polyethylene glycol, polyethylene glycol-block-polypropylene glycol-block-polyethylene glycol polymer, polypropylene glycol-block-polyethylene glycol-block-polypropylene and mixtures thereof, 1,1?-Carbonyldiimidazole, polyamine and mixtures thereof.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: August 15, 2023
    Assignee: The Procter & Gamble Company
    Inventors: Travis Kyle Hodgdon, Douglas Michael Graham, Freddy Arthur Barnabas, Corey James Kenneally, Christopher Bryant Williams, Callie Elizabeth Zawaski, Timothy E Long, Allison M Pekkanen, Benjamin Tyler White
  • Patent number: 11707499
    Abstract: The invention discloses odor masking formulations for stench natural compounds, selected from the extracts, fraction and pure phytochemicals that are produced in combination with a natural or synthetic hydrocolloid polymer gum(s). The invention further discloses novel process of producing the odor and taste masking formulations. The invention also discloses taste masking formulations of valerian extracts with no characteristic stench odor & or negligible stench odor in combination with natural hydrocolloid gum such as guar gum, acacia or other polymers. The invention further discloses method of reducing insomnia, anxiety, Attention Deficit Disorder (ADD), Chronic Fatigue Syndrome (CFS) using odor masking formulation of the current invention. Importantly, the said odor masked formulation of the present disclosure helps in improving sleep cycle and helps in efficient functioning of brain.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: July 25, 2023
    Assignee: LAILA NUTRACEUTICALS
    Inventors: Ganga Raju Gokaraju, Rama Raju Gokaraju, Kishore Babu Govada, Venkata Krishna Raju Alluri, Nagendra Babu Vutti, Kiran Bhupathiraju, Venkata Kanaka Ranga Raju Gokaraju, Trimurtulu Golakoti
  • Patent number: 11701320
    Abstract: A mineralization agent, including, by weight: 5-50% of a film-forming protein, 5-40% of an amelogenin peptide, 5-30% of a water-soluble phosphate, 4-20% of a tris(2-carboxyethyl) phosphine hydrochloride, and 1-10% of a pH regulator. The film-forming protein is selected from the group consisting of lysozyme, bovine serum protein, insulin, ?-lactalbumin, or a mixture thereof.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: July 18, 2023
    Assignee: MEIYOU (XI'AN) BIOTECHNOLOGY CO., LTD.
    Inventors: Peng Yang, Dong Wang
  • Patent number: 11696893
    Abstract: The present invention aims to provide a preparation expected to improve the bitter taste of an organic acid salt of vonoprazan and permit rapid dissolution of the organic acid salt of vonoprazan after administration. The present invention provides a preparation containing fine granules or granules containing (1) a core granule containing an organic acid salt of vonoprazan, (2) an intermediate layer containing the same organic acid as the organic acid forming the salt of vonoprazan in (1), or a salt thereof, and (3) a coating layer containing a water-insoluble polymer.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: July 11, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Hiroyuki Fujii, Akira Suzuki
  • Patent number: 11690863
    Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: July 4, 2023
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
  • Patent number: 11679068
    Abstract: Ultraviolet radiation sun protective compositions are reported which feature micronized metal oxide inorganic particles selected from zinc oxide, titanium dioxide and mixtures thereof, the inorganic particles being coated with an adduct of a hydroxy cinnamate and a silanol, amounts of the adduct to the inorganic particles being in a relative weight ratio of 1:200 to 1:4.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: June 20, 2023
    Assignee: VIZOR, LLC
    Inventors: Yannick Rigg, Richard Rigg
  • Patent number: 11679168
    Abstract: Embodiments of the synthesis, radiolabeling and biological applications of an activatable tracer that undergoes intramolecular cyclization and aggregation upon activation by cleavage of a blocking moiety are provided. The probes of the disclosure allow for target-controlled self-assembly of small molecules in living subjects for imaging and drug delivery. The aggregated nanoprobes of the disclosure may be detectable optically, by PET detection, magnetic resonance imaging, and the like depending on the detectable reporter attached to the nanoprobe.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: June 20, 2023
    Assignee: The Board of Trustees of Leland Stanford Junior University
    Inventors: Jianghong Rao, Yunfeng Cheng, Min Chen, Jianghang Xie, Zixin Chen
  • Patent number: 11672765
    Abstract: In one aspect, the present disclosure provides microparticles that are configured to release a first drug over a first time period and to release a second drug over a second time period, wherein a lag period of substantially no drug release occurs between the first and second time periods. In other aspects, the present disclosure pertains to the use of such microparticles in delivery systems and methods of treatment. In another aspect, the present disclosure pertains to drug delivery systems that comprising a folded inflatable drug delivery balloon that comprises folds and microparticles positioned within the folds.
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: June 13, 2023
    Assignee: BOSTON SCIENTIFIC SCIMED, INC.
    Inventors: Javier Palomar-Moreno, Michelle Hannon, Phillip Bannister
  • Patent number: 11666538
    Abstract: The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric polymer; and (b) an immediate release component comprising carbidopa and levodopa.
    Type: Grant
    Filed: October 4, 2022
    Date of Patent: June 6, 2023
    Assignee: Impax Laboratories, LLC
    Inventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
  • Patent number: 11660331
    Abstract: An improved heroin conjugate vaccine is detailed; to accomplish this task the systematic exploration of twenty vaccine formulations with varying combinations of carrier proteins and adjuvants were undertaken. In regard to adjuvants, a Toll-like receptor 9 (TLR9) agonist and a TLR3 agonist in the presence of alum were explored. The vaccine formulations containing TLR3 or TLR9 agonist alone-elicited strong anti-heroin antibody titers and blockade of heroin-induced antinociception when formulated with alum; however, a combination of TLR3 and 9 adjuvants did not result in improved efficacy. Investigation of stability of the two lead formulations revealed that the TLR9 but not the TLR3 formulation was stable when stored over 30 days. Furthermore, mice immunized with the TLR9+alum heroin vaccine gained significant protection from lethal heroin doses, suggesting that this vaccine formulation is suitable for mitigating the lethal effects of heroin, even following long-term storage at room temperature.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: May 30, 2023
    Assignee: The Scripps Research Institute
    Inventor: Kim D. Janda
  • Patent number: 11648206
    Abstract: Pharmaceutical compositions of colchicine for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined or desired release profile. Methods of treating or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein are also provided.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: May 16, 2023
    Assignee: MURRAY AND POOLE ENTERPRISES LTD
    Inventor: Susanne Riel
  • Patent number: 11648569
    Abstract: The present invention relates to the use for ore beneficiation, of at least one derivative of alkoxylated (polyester)amine. The present invention also relates to the flotation pulp and the tailings comprising said product useful for ore beneficiation.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: May 16, 2023
    Assignee: Arkema France
    Inventors: Eric Jorda, Alain Baloche, Nathalie Gibert, Isabelle Birken, Gilles Barreto, Jean-Paul Gamet
  • Patent number: 11634604
    Abstract: Loose particulate materials can be problematic in various aspects. For example, loose particulate materials may generate dust or be difficult to consolidate together. Fines in loose particulate materials may also be an issue. Coated particulates may alleviate some of the foregoing issues. Suitable coated particulates may comprise a particulate material comprising sand or a ceramic, and a polysaccharide composition coated upon the particulate material, the polysaccharide composition comprising a functionalized polysaccharide. Other particulate materials such as wood chips and animal litter particulates may be coated with functionalized polysaccharides to achieve similar advantages.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: April 25, 2023
    Assignee: Integrity Bio-Chemicals, LLC
    Inventors: Ashoka V. R. Madduri, Christopher P. Gardner, Sanket Gandhi, Matthew B. Blackmon, Charles R. Landis, Curtis J. Rodencal
  • Patent number: 11633447
    Abstract: A composition according to an embodiment of the present disclosure includes a banaba leaf extract, a guava leaf extract or a mixture thereof. The composition inhibits photooxidation of A2E due to blue light, inhibits a death of retinal pigment epithelial cells induced by blue light, and inhibits a damage to outer nuclear layers of visual cells in an animal model with blue light-induced macular degeneration, and thus can be beneficially used as a composition for preventing or treating macular degeneration and as a health functional food for preventing or alleviating macular degeneration.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: April 25, 2023
    Assignee: LEMONEX INC.
    Inventors: Cheol Hee Won, Jun Kim
  • Patent number: 11622941
    Abstract: The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric polymer; and (b) an immediate release component comprising carbidopa and levodopa.
    Type: Grant
    Filed: July 10, 2021
    Date of Patent: April 11, 2023
    Assignee: Impax Laboratories, LLC
    Inventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
  • Patent number: 11612592
    Abstract: Liquid formulations containing picosulfate and magnesium citrate are provided. The compositions can include one or more precipitation inhibitors such as carboxylic acids (e.g., malonic acid), soluble anionic polymers and ammonium salts. The formulations are useful to treat constipation or for the clearance of the bowel prior to X-ray examination, endoscopy or surgery.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: March 28, 2023
    Assignee: FERRING B.V.
    Inventors: Alfred Chi-Yeh Liang, Nipul Ghanshyambhai Patel, Jian-Xin Li
  • Patent number: 11607420
    Abstract: The present invention relates to a new formulation of specific nutritional ingredients (nutraceuticals) and/or pharmaceutical compounds.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: March 21, 2023
    Assignee: DSM IP ASSETS B.V.
    Inventors: Elger Funda, Odile Krainz
  • Patent number: 11596645
    Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.
    Type: Grant
    Filed: October 27, 2021
    Date of Patent: March 7, 2023
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
  • Patent number: 11596669
    Abstract: The present disclosure relates to liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate and prefilled syringe or autoinjector comprising liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate.
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: March 7, 2023
    Assignee: 89BIO, INC.
    Inventors: Boris Schwartsburd, Shaji Joseph
  • Patent number: 11583497
    Abstract: The invention provides ocular formulations and features a nano-emulsion composition, e.g., a nano-emulsion comprising a CBF?-RUNX1 inhibitor. The composition comprises a particle with a length of less than 200 nanometers in at least one dimension.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: February 21, 2023
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Leo A. Kim, Joseph F. Arboleda-Velasquez
  • Patent number: 11576886
    Abstract: The present invention relates to a construct comprising a C13 to C27 fatty acid non-covalently bound to a hydrophobic region of a carrier particle, methods of manufacture, and uses thereof.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: February 14, 2023
    Assignee: Polyrem Limited
    Inventors: Tony Davies, Deirdre McIntosh, Malcolm Weetman
  • Patent number: 11564888
    Abstract: The present disclosure provides extended release trihexyphenidyl compositions suitable for once- or twice-daily administration. The compositions comprise a core comprising organic acid that is coated with at least one drug layer comprising trihexyphenidyl hydrochloride, and a functional coat over the drug-layered core. The extended release compositions of the disclosure provide extended release of trihexyphenidyl hydrochloride, with reduced Cmax, and a Cmin:Cmax ratio of ?0.4, while maintaining a therapeutically effective concentration for a period of at least about 16 hours. The compositions of the disclosure improve solubility of trihexyphenidyl hydrochloride, at a pH of greater than or equal to 5, to maintain its minimum effective concentration at such pH.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: January 31, 2023
    Assignee: Amneal Complex Products Research LLC
    Inventors: Namdev B. Shelke, Siva Ram Kiran Vaka, Navnit H. Shah, Dipen Desai, Wantanee Phuapradit
  • Patent number: 11559494
    Abstract: In one aspect, compositions are described herein. A composition described herein comprises a nanoparticle, a therapeutic species, and a linker joining the nanoparticle to the therapeutic species. The linker joining the nanoparticle to the therapeutic species comprises a Diels-Alder cyclo-addition reaction product. Additionally, in some embodiments, the nanoparticle is a magnetic nanoparticle.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: January 24, 2023
    Assignee: THE PENN STATE RESEARCH FOUNDATION
    Inventors: Daniel J Hayes, Mohammad Abu-Laban
  • Patent number: 11534406
    Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: December 27, 2022
    Assignee: Tillotts Pharma AG
    Inventors: Felipe José Oliveira Varum, Roberto Carlos Bravo González, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
  • Patent number: 11524072
    Abstract: A vaccine delivery method is presented that includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also included are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: December 13, 2022
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: Donald A. Harn, Rafaella Queiroz, Lisa Shollenberger, Emily-Joy Farah Samli
  • Patent number: 11517534
    Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: December 6, 2022
    Assignee: Tillotts Pharma AG
    Inventors: Felipe Josè Oliveira Varum, Roberto Carlos Bravo González, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
  • Patent number: 11517588
    Abstract: The present disclosure provides a nanoparticle, a preparation process thereof, a method for treating cancer, a method for enhancing effect of a liver cancer drug, a method for ameliorating tumor hypoxia, and a method for enhancing effect of a liver cancer vaccine by using the nanoparticle.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: December 6, 2022
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventors: Yun-Ching Chen, Tsai-Te Lu, Yun-Chieh Sung
  • Patent number: 11517610
    Abstract: A bone repair material, a preparation method of the bone repair material, and a biological composite scaffold are provided. The bone repair material includes: a base material, and a carbon nanomaterial and a polypeptide both mixed with the base material; and the carbon nanomaterial and the polypeptide are bonded by chemical bonds. The preparation method includes: bonding a carbon nanomaterial with a polypeptide by chemical bonds; and mixing the carbon nanomaterial and the polypeptide bonded by the chemical bonds with a base material, and performing a molding treatment.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: December 6, 2022
    Assignee: BEIJING BOE TECHNOLOGY DEVELOPMENT CO., LTD.
    Inventors: Tianxiao Zhao, Zhichao Li, Changjun Liu, Xianzhen Li, Tianyue Zhao
  • Patent number: 11504431
    Abstract: Provided herein are fluid formulations for administration to a suprachoroidal space of an eye of a patient. The fluid formulations may include a pharmaceutical agent, a binding molecule, or a combination thereof. The pharmaceutical agent and the binding molecule may be bonded to each other covalently, non-covalently, or a combination thereof. The pharmaceutical agent may be configured to bond to an ocular tissue. The binding molecule may be configured to bond to an ocular tissue. Methods of administering the fluid formulations, methods of expanding a suprachoroidal space, and methods of reducing the minimum force to separate the sclera and choroid are provided.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: November 22, 2022
    Assignees: Emory University, Georgia Tech Research Corporation
    Inventors: Mark R. Prausnitz, Bryce Chiang
  • Patent number: 11504337
    Abstract: The disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human methylmalonyl-CoA mutase precursor, human methylmalonyl-CoA mutase (MCM) mature form, or functional fragments thereof. In some embodiments, the disclosure includes methods of treating methylmalonic acidemia in a subject in need thereof comprising administering an mRNA encoding an MCM polypeptide.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: November 22, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Paolo Martini, Vladimir Presnyak, Kerry Benenato, Stephen Hoge, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe
  • Patent number: 11478505
    Abstract: Provided herein are compositions comprising ixabepilone, or a pharmaceutically acceptable salt thereof, and a copolymer represented by formula I: Also provided are methods of treating cancer using the compositions described herein, and methods of preparing the compositions.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: October 25, 2022
    Assignee: R-Pharm US Operating LLC
    Inventors: Kevin N. Sill, Bradford T. Sullivan
  • Patent number: 11471564
    Abstract: An object of the present invention is to provide an angiogenic agent that can sufficiently exhibit an angiogenic effect due to mesenchymal stem cells in a state where the angiogenic agent does not allow permeation of host cells while being protected from immune rejection, and a method for method for manufacturing the same. According to the present invention, an angiogenic agent including a mesenchymal stem cell (A); and an immunoisolation membrane (B) that encloses the mesenchymal stem cell is provided.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: October 18, 2022
    Assignee: FUJIFILM Corporation
    Inventors: Kentaro Nakamura, Ryo Kogawa
  • Patent number: 11464811
    Abstract: A production method of microencapsulated probiotics with chitosan-alginate polymers, the microcapsules loaded with probiotics obtained by this method and their use in food, agriculture and cosmetics. The microcapsules do not make alterations in the color and appearance of the product in which they are applied and have antifungal and anti-mycotoxin features.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: October 11, 2022
    Assignee: NANOMIK BIYOTEKNOLOJI A.S.
    Inventor: Buse Berber
  • Patent number: 11464740
    Abstract: Methods and monodisperse glass microsphere composites comprising a porous wall hollow-glass microsphere; a cargo of a therapeutic is loaded inside of the porous wall hollow-glass microsphere; and a first shell fully encapsulating the porous wall hollow-glass microsphere and capping pores in the walls, retaining the cargo inside of the porous wall hollow-glass microsphere.
    Type: Grant
    Filed: April 29, 2020
    Date of Patent: October 11, 2022
    Assignees: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE, MUSC FOUNDATION FOR RESEARCH DEVELOPMENT, APPLIED RESEARCH CENTER, INC.
    Inventors: Paul M. Weinberger, George Wicks, William D. Hill
  • Patent number: 11458133
    Abstract: Disclosed herein are methods for treating solid tumors by direct injection into the tumors of chemotherapeutic particles, methods for inhibiting tumor metastasis by administering chemotherapeutic particles to a subject having a tumor, and compositions that include chemotherapeutic particles, small amounts of a polysorbate, and a carrier.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: October 4, 2022
    Assignee: CritiTech, Inc.
    Inventors: Mike Baltezor, Gere diZerega, Charles Decedue, Sam Campbell, Matt McClorey
  • Patent number: 11458112
    Abstract: Methods, pharmaceutical formulations, and kits are provided for using capsaicin to effectuate voluntary defecation in mammals who cannot defecate without external invasion of the bowel or those who defecate involuntarily (i.e., those having fecal incontinence). The pharmaceutical formulations and kits can also be useful for inducing defecation in mammals that do not have defecation dysfunction such as, for example, in a person who is unconscious and may defecate unconsciously or in a pet at a convenient location at a specific time. The methods and compositions provide patients with defecation dysfunction control over when and where they defecate.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: October 4, 2022
    Assignee: DIGNIFY THERAPEUTICS, LLC
    Inventors: Karl Bruce Thor, Lesley Marson
  • Patent number: 11458153
    Abstract: This invention discloses drug-delivery compositions, methods of making prodrugs, and methods of drug delivery using a self-assembled gelator. The backbone of the gelator can contain a drug or prodrug, such as acetaminophen or salicin. Additional drugs or agents can be encapsulated in the gelator. Enzymatic or hydrolytic cleavage can be used to release the drugs.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: October 4, 2022
    Assignees: The City University of New York, represented by The Research Foundation of the City University of New York, The Brigham and Women's Hospital Inc.
    Inventors: Jeffrey M. Karp, Praveen Kumar Vemula, George John, Greg Cruikshank
  • Patent number: 11446245
    Abstract: Provided is a composition including a first phase comprising a first filler; a second phase, the second phase comprising a second filler; and a third phase comprising a third filler; and a fourth phase comprising a fourth filler; and a first active ingredient, wherein the first active ingredient is selected from the group consisting of caffeine, Echinacea purpurea, Echinacea angustifolia, Echinacea pallida, Acmella oleracea, Helichrysum umbraculigerum, Radula marginata, kava, kanna, black truffle, Syzygium aromaticum, Rosmarinus oficinalis, basil, oregano, lavender, true cinnamon, malabathrum, cananga odorata, Riboflavin, theanine, Ginkgo Biloba, Bacopa, Rhodiola Rosea, and combinations thereof.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: September 20, 2022
    Assignee: NULIXIR INC.
    Inventor: Ehsan Moaseri
  • Patent number: 11427661
    Abstract: The present invention provides a fluorescent polymer comprising a fluorophore perylene bisimide (PBI) and oligo (p-phenylene vinylene) (OPV) functionalized with carboxy and amine functionality groups and a polystyrene (PS) backbone for the detection of volatile organic compound, a process for the detection and a kit thereof.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: August 30, 2022
    Assignee: Council of Scientific & Industrial Research
    Inventors: Sarabjot Kaur Makkad, Asha Syamakumari